<DOC>
	<DOCNO>NCT01230827</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety golimumab ( CNTO 148 ) patient active juvenile idiopathic arthritis ( JIA ) least 5 joint active arthritis poor response methotrexate .</brief_summary>
	<brief_title>A Study Safety Efficacy CNTO 148 ( Golimumab ) Children With Juvenile Idiopathic Arthritis ( JIA ) Multiple Joint Involvement Who Have Poor Response Methotrexate ( GO KIDS )</brief_title>
	<detailed_description>Approximately 170 juvenile patient take part study worldwide . All patient receive 30mg/m2 ( milligram per meter square , 50 mg per dose ) golimumab subcutaneously ( injection skin ) every 4 week Week 0 Week 12 . At Week 16 , patient show least 30 percent improvement sign symptom start study randomize receive either placebo ( sham medicine injection ) 30 mg/m2 golimumab injection every 4 week week 16 week 48 . If patient get markedly bad receive placebo injection , restart golimumab next scheduled visit continue golimumab . Patients leave study time without question . Between Week 48 analysis timepoint Week 144 , subsequently amend Week 248 , patient receive golimumab 30mg/meter square , unless , measurement , nearly cure ( clinical remission ) placebo , whereby discontinue study . Patients may change background treatment Week 48 base therapeutic effect . Patients continue active treatment Week 48 long-term extension Week 144 , subsequently amend Week 248 . All patient receive fix dose commercial methotrexate throughout study duration . Safety monitor 152 week , subsequently amend 256 week include draw blood look laboratory test , vital sign ( eg , blood pressure ) , frequency type adverse event ( side effect ) .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Diagnosis must patient 's 16th birthday Disease duration least 6 month study entry Must 5 joint active arthritis Must take stable dose methotrexate 1030 mg/meter square ( patient body surface area [ BSA ] 1.67 square meter must take minimum 15 mg/week methotrexate ) May take stable dose prednisone less 10 mg/day 4 week prior entry may take stable dose NSAIDS ( nonsteroidal antiinflammatory drug ) 2 week prior entry Must qualify laboratory value first visit . Have know allergy , hypersensitivity , intolerance golimumab similar therapeutic Are pregnant breastfeeding , plan pregnancy father child within 6 month last study agent administration Have initiate DMARDS and/or immunosuppressive therapy within 4 week prior study initiation</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Juvenile Idiopathic Arthritis</keyword>
	<keyword>golimumab</keyword>
	<keyword>juvenile arthritis</keyword>
	<keyword>GO KIDS</keyword>
	<keyword>anti TNF alpha medication</keyword>
	<keyword>juvenile psoriatic arthritis</keyword>
</DOC>